Navigation Links
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study

CRANBURY, N.J., March 14, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

"We are so pleased that Cornerstone has received a report from NCI indicating that Emulsiphan appears to be safe and capable as a drug delivery solution for anticancer agents," said Dr. Robert Shorr, CEO of Cornerstone Pharmaceuticals, Inc.

"Combining anticancer agents with a targeted drug delivery technology, such as Emulsiphan, could greatly improve patient outcomes. We look forward to the next phase of preclinical study in our ongoing collaboration with NCI."

The preclinical study, which looked at the safety of azide drug-loaded Emulsiphan nano emulsions, is the first step in a collaboration between Cornerstone and NCI to apply Cornerstone's drug delivery platform to a class of novel chemotherapy agents developed by Dr. Yossef Raviv in the laboratory of the renowned biologist Dr. Robert Blumenthal at NCI's Center for Cancer Research Nanobiology Program.

Selective drug delivery remains a formidable challenge in the successful treatment of cancer. Often, just a small percentage of the active ingredients in chemotherapies administered to treat tumors ever reach the desired target within cancer cells and considerable amounts of drug spread to healthy cells and tissue.

Emulsiphan is a novel, cancer selective drug-delivery nanotechnology that aims to deposit cancer-fighting drugs directly into cancer cells--not just the tumor mass--by focusing on the distinct metabolism of these cells.  The nanotechnology is designed to maximize drug concentration into tumor cells, thereby enhancing the anti-cancer compounds' selectivity and specificity, leading to a potentially safer and more effective cancer treatment.

About Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals, Inc. is a privately held company committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone currently has a drug in clinical trials targeting enzymes crucial to cancer cell metabolism.  AEMD compounds, the company's unique approach to cancer treatment, is the leading platform in cancer metabolism.  It has facilitated the discovery of first-in-class drugs and a novel drug delivery technology - both with the potential to transform the way cancer is treated.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.Media Contact: Meghan WeberLiza Sullivan & Associates(917) 399-8713

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
2. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
3. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
9. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
10. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
11. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Post Your Comments:
(Date:11/26/2015)... WILMINGTON, North Carolina , 26 november ... Laboratories, Inc. (AAIPharma/CML) kondigt de geplande investering ... de uitbreiding van de laboratoria en het ... . De uitbreiding zal resulteren in ... waarmee wordt voldaan aan de groeiende behoeften ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Indosoft Inc., developer ... of an application server to improve system efficiency and reliability. , The new Q-Suite ... of these standards, the system avoids locking itself into a specific piece of software ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday ... dish and pleasing the palates of attendees is of the utmost importance. Whether ... a seasonal get-together, give these recipes a try this holiday season. , Turkey ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo ... parts and accessories. , Sauna accessories help improve the bather experience in the ... From basic styles for the purist looking for simplicity in design to accessories ...
(Date:11/25/2015)... ... 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a ... behalf of a home health care worker who provided companionship services for the elderly, ... workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), ...
Breaking Medicine News(10 mins):